Loading...
•
Sep 30, 2021
Merck Q3 2021 Earnings Report
Merck delivered a strong quarter with positive momentum and progress across the pipeline.
Key Takeaways
Merck announced strong Q3 2021 financial results, driven by key products like KEYTRUDA and GARDASIL. The company is also advancing its pipeline with positive Phase 3 results for molnupiravir and the planned acquisition of Acceleron.
Merck achieved notable clinical milestones in oncology and COVID-19.
Positive Phase 3 results were reported for molnupiravir.
The company announced a proposed acquisition of Acceleron to strengthen its cardiovascular portfolio.
Merck is focused on expanding its portfolio and pipeline for long-term success.
Revenue by Segment
Forward Guidance
Merck is raising and narrowing its full-year estimated ranges for revenue and EPS.
Positive Outlook
- Sales growth of 14% to 15% is expected in 2021.
- Full-year 2021 revenue is estimated to be between $47.4 billion and $47.9 billion.
- GAAP EPS range is raised and narrowed to be between $4.71 and $4.76.
- Non-GAAP EPS range is raised and narrowed and now expects full-year 2021 to be between $5.65 and $5.70.
- The pandemic will have a net unfavorable impact to 2021 revenues of less than 3%.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...